Biochemistry and molecular cell biology of diabetic complications

Nature

Volumn 414, Issue 6865, 2001, Pages 813-820

  Brownlee, M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY; DISEASES; DRUG PRODUCTS; GLUCOSE; RISKS;

NERVE DAMAGE;

BIOCHEMISTRY;

SUPEROXIDE;

BIOCHEMISTRY; DIABETES;

ATHEROSCLEROSIS; BLINDNESS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; HEART INFARCTION; KIDNEY FAILURE; NERVE INJURY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; RISK FACTOR; STROKE;

DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FORECASTING; GLYCOSYLATION END PRODUCTS, ADVANCED; HEXOSAMINES; HUMANS; HYPERGLYCEMIA; PROTEIN KINASE C;

EID: 0035856980     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/414813a     Document Type: Review

References (100)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
3. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study
4. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice
5. Insulin resistancecardiovascular disease
6. Atherosclerosis
7. Cardiovascular risk continuum: Implications of insulin resistance and diabetes
8. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats
9. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo
10. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation
11. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbAlc levels
12. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications
13. Identification of the mechanism for the inhibition of Na,K-adenosine triphosphatase by hyperglycemia involving act Nation of protein kinase C and cytosolic phospholipase A2
14. Hyperglycemic pseudohypoxia and diabetic complications
15. Diabetic endothelial dysfunction: The role of poly (ADP-ribose) polymerase activation
16. Contributions of polyol pathway to oxidative stress in diabetic cataract
17. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs
18. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy
19. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy
20. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats
21. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy
22. Chemical modification of proteins by methylglyoxal
23. Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose
24. The glyoxalase system: New developments towards functional characterization of a metabolic pathway fundamental to biological life
25. Overexpression of aldehyde reductase protects PC12 cells from the cytotoxicity of methylglyoxal or 3-deoxyglucosone
26. Retardation by amitoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat
27. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB. 9195, a novel inhibitor of advanced glycation
28. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
29. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes
30. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation end product formation and prevents hyperglycemia-induced increases in macromolecular endocytosis
31. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
32. Glycation induces expansion of the molecular packing of collagen
33. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats
34. The effect of nonenzymatic glucosylation the binding of the main noncollagenous NCl domain to type IV collagen
35. Laminin alterations after in vitro nonenzymatic glucosylation
36. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen
37. Nonenzymatic glycosylation of laminin and the laminin peptide CIKVAVS inhibits neurite outgrowth
38. Molecular identity and cellular distribution of advanced glycation end product receptors: Relationship of p60 to OST-48 and p90 to 80K-H membrane proteins
39. Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal kupffer and endothelial cells
40. Identification of galectin-3 as a high-affinity, binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor
41. Cloning and expression of RAGE: A cell surface-receptor for advanced glycosylation end products of proteins
42. Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling
43. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation and product modified protein
44. Synthesis and secretion of macrophage colony stimulating factor by mature human monocytes and human monocytic THP-1 cells induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation end products
45. Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodelling and diabetic nephropathy
46. Receptor specific increase in extracellular matrix productions in mouse mesangial cells by advanced glycosylation end products is mediated via platelet derived growth factor
47. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes
48. Advanced glycation endproducts increase retinal vascular endothelial growth factor expression
49. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
50. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
51. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress
52. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells
53. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells
54. Protein kinase C activation and the development of diabetic complications
55. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia
56. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats
57. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure
58. G. Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation
59. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
60. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response
61. Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin
62. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo a specific vascular action of insulin
63. High glucose alters the response of mesangial cell protein kinase C isoforms to endothelin-1
64. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha
65. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro
66. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium
67. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats
68. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells
69. Regulation of the laminin Cl promoter in cultured mesangial cells
70. Role of protein kinase C in glucose- and angiotensin II-induced plasminogen activator inhibitor expression
71. Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: Prevention by calphostin C
72. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells
73. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes
74. High glucose-induced transforming growth factor beta 1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells
75. Discovery of a metabolic pathway mediating glucoseinduced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance
76. Role of the glucosamine pathway in fat-induced insulin resistance
77. Sp1 sites mediate activation of the plasminogen activator inhibitor- 1 promoter by glucose in vascular smooth muscle cells
78. Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through Spl DNA binding sites in glomerular mesangial cells
79. Distinct regions of Sp1 modulate DNA binding and transcriptional activation
80. Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-Nacetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate
81. Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins
82. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the AKT site
83. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens
84. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
85. Oxidative stress and diabetic vascular complications
86. BCL-2 expression or antioxidants prevent hyperglycemiainduced formation of intracellular advanced glycation endproducts in bovine endothelial cells
87. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria
88. 2+ superoxide dismutase suppresses increases in collagen accumulation induced by culture in measangial cells in high media glucose
89. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction
90. z4 superoxide dismutase protects against early diabetic glomerular injury in transgenic mice
91. Progression of incipient diabetic retinopathy during good glycemic control
92. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
93. Familial factors determine the development of diabetic nephropathy in patients with IDDM
94. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial
95. Familial aggregation of coronary artery calcium in families with type 2 diabetes
96. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy
97. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus
98. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICROHOPE substudy
99. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats